This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
National Vision (EYE) Down 6.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Implied Volatility Surging for National Vision (EYE) Stock Options
by Zacks Equity Research
Investors need to pay close attention to National Vision (EYE) stock based on the movements in the options market lately.
Prestige Consumer's (PBH) Q1 Earnings Beat, Margins Shrink
by Zacks Equity Research
Prestige Consumer (PBH) first-quarter sales bear the brunt of the ongoing supply chain challenges in the Clear Eyes business.
Insulet (PODD) Q2 Earnings Miss Estimates, '24 Sales View Raised
by Zacks Equity Research
Insulet's (PODD) second-quarter performance benefits from the continued high demand for Omnipod 5.
National Vision (EYE) Tops Q2 Earnings, Lowers '24 Outlook
by Zacks Equity Research
National Vision (EYE) delivers an earnings beat in the second quarter of 2024 and announces new transformative actions for long-term growth.
National Vision (EYE) Q2 Earnings Beat Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 150% and 2.83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Should Value Investors Buy National Vision (EYE) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
EYE vs. PODD: Which Stock Is the Better Value Option?
by Zacks Equity Research
EYE vs. PODD: Which Stock Is the Better Value Option?
Will WATCHMAN Sales Aid Boston Scientific's (BSX) Q2 Earnings?
by Zacks Equity Research
In EMEA, Boston Scientific (BSX) is expected to have registered growth within structural heart, including Transcatheter aortic valve replacement, WATCHMAN and other interventional cardiology therapies.
Is a Beat Likely for Edwards Lifesciences (EW) in Q2 Earnings?
by Zacks Equity Research
Edwards Lifesciences' (EW) TMTT segment's PASCAL platform is likely to have maintained strong growth momentum in the second quarter globally, backed by its portfolio of differentiated therapies.
Are Investors Undervaluing National Vision (EYE) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Strength Seen in National Vision (EYE): Can Its 7.2% Jump Turn into More Strength?
by Zacks Equity Research
National Vision (EYE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
EYE or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EYE vs. SYK: Which Stock Is the Better Value Option?
National Vision (EYE) Gains Market Share Despite Macro Woes
by Zacks Equity Research
National Vision (EYE) continues to execute core growth initiatives and further invest in strengthening competitive advantages.
National Vision (EYE) Down 4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
National Vision (EYE) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
National Vision (EYE) delivers improved revenues in the first quarter of 2024 in a challenging macro environment.
National Vision (EYE) Q1 Earnings Top Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 7.14% and 2.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Jushi Holdings Inc. (JUSHF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Jushi Holdings Inc. (JUSHF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: National Vision (EYE) Q1 Earnings Expected to Decline
by Zacks Equity Research
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
National Vision (EYE) Down 4.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
The strong execution of strategic initiatives and robust financial stability bode well for National Vision (EYE).
National Vision (EYE) Q4 Earnings Top Estimates, Margins Fall
by Zacks Equity Research
National Vision's (EYE) Q4 adjusted comparable store sales growth is driven by ongoing strength within America's Best and Eyeglass World sales.
Stock Market News for Feb 28, 2024
by Zacks Equity Research
Wall Street closed with a mixed performance on Tuesday as investors awaited crucial inflation data, which could influence the Federal Reserve's interest rate decisions.
National Vision (EYE) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for National Vision (EYE) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Countdown to National Vision (EYE) Q4 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of National Vision (EYE) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.